Cite
358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
MLA
Donna M. Fitzgerald, et al. “358TiP Phase Ib/II Study of Antibody-Drug Conjugate, Sacituzumab Govitecan, in Combination with the PARP Inhibitor, Talazoparib, in Metastatic Triple-Negative Breast Cancer.” Annals of Oncology, vol. 31, Sept. 2020, p. S394. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........eaad59d75b99fcbed45f979a94ac87e7&authtype=sso&custid=ns315887.
APA
Donna M. Fitzgerald, Jeffrey Peppercorn, AH Partridge, Heather A. Parsons, Sara M. Tolaney, Irene Kuter, Jennifer A. Ligibel, Dejan Juric, Paula D. Ryan, Elene Viscosi, V. Attaya, Laura Spring, M. Shellock, Aditya Bardia, Beverly Moy, B. Lormill, D. Chawla, & Leif W. Ellisen. (2020). 358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer. Annals of Oncology, 31, S394.
Chicago
Donna M. Fitzgerald, Jeffrey Peppercorn, AH Partridge, Heather A. Parsons, Sara M. Tolaney, Irene Kuter, Jennifer A. Ligibel, et al. 2020. “358TiP Phase Ib/II Study of Antibody-Drug Conjugate, Sacituzumab Govitecan, in Combination with the PARP Inhibitor, Talazoparib, in Metastatic Triple-Negative Breast Cancer.” Annals of Oncology 31 (September): S394. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........eaad59d75b99fcbed45f979a94ac87e7&authtype=sso&custid=ns315887.